X
All Data
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): EB005
Therapeutic Area: Dermatology Product Name: EB005
Highest Development Status: Discovery Product Type: Undisclosed
Partner/Sponsor/Collaborator: GlaxoSmithKline
Deal Size: $224.0 million Upfront Cash: Undisclosed
Deal Type: Collaboration January 11, 2021
Details:
Eligo will receive an upfront payment and R&D funding to advance EB005, until preclinical proof of concept. If GSK exercises its option, GSK and Eligo will enter into a license and collaboration agreement to jointly continue the development of EB005 in acne.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
